Children with acute malnutrition across Africa and Asia have a higher risk of treatment failure and malaria reinfection, even after being given the best currently available and recommended malaria treatment.
Prabotulinumtoxin A biosimilar by AEON Biopharma for Spasmodic Torticollis (Cervical Dystonia): Likelihood of Approval
Prabotulinumtoxin A biosimilar is under clinical development by AEON Biopharma and currently in Phase II for Spasmodic Torticollis (Cervical Dystonia).